Why Is Tyra Biosciences Stock Sinking Wednesday?
Tyra Biosciences stock fell sharply as initial dabogratinib Phase 2 data showed a 57% complete response rate at 60 mg.
Tyra's medicine showed it worked well in early tests (57% of patients improved), but investors sold the stock anyway—maybe they hoped for even better results. When a company's medicine works but the stock drops, it's worth watching to see if the company explains what they'll do next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.